Bicara Therapeutics BCAX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Liquidity | ||||||
| Current ratio | 13.9×— | 14.6×— | 14.1×— | 25.8×— | —— | |
| Quick ratio | 13.9×— | 14.6×— | 14.1×— | 25.8×— | —— | |
| Cash ratio | 8.2×— | 3.3×— | 8.2×— | 25.3×— | —— | |
| Leverage | ||||||
| Debt-to-equity | 0×— | 0×— | 0×— | 0×— | —— | |
| Debt-to-assets | 0×— | 0×— | 0×— | 0×— | —— | |
| Per Share | ||||||
| Book value per share | $8.46+0.4% | $7.34-74.9% | $7.38-84.2% | $7.98+104% | $8.43— | |
| Valuation | ||||||
| Market capitalization | $1.29B— | $921.98M— | $861.55M— | —— | —— | |
| Enterprise value | $966.81M— | $827.01M— | $691.85M— | —— | —— | |
| Price / book | 2.5×— | 2.3×— | 2.1×— | —— | —— | |
| Free cash flow yield | -9%— | -11.6%— | -13.1%— | —— | —— | |
| Earnings yield | -12.2%— | -15%— | -14.1%— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Bicara Therapeutics's ratios come from?
- Every ratio is computed from Bicara Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.